Multiple sclerosis (MS) is an autoimmune disease in which myelin proteins have been implicated as autoantigens recognized by pathogenic autoreactive T cells. To study the relationship between human myelin basic protein (hMBP) and HLA alleles associated to MS susceptibility, such as DRB1*1501, the binding of synthetic peptides spanning the entire hMBP sequence to 10 purified HLA-DR molecules was determined. All the hMBP peptides tested showed binding affinity for at least one of the DR molecules analyzed, but three hMBP peptides, included in sequences 13-32,84-103, and 144-163 were found capable of binding to three or more DR molecules. The hMBP peptide 84-103 was the most degenerate in binding, in that it bound to 9 out of 10 DR molecules tested. Interestingly, it bound with highest affinity to DRB1*1501 molecules. To correlate the binding pattern of hMBP peptides to HLA class II molecules with their recognition by T cells, 61 hMBP-specific T cell lines (TCL) were established from the peripheral blood of 20 MS patients, who were homozygous, heterozygous, or negative for DRB1*1501. Analysis of hMBP epitopes recognized by these TCL and their HLA restriction demonstrated a very good correlation between binding data and T cell proliferation to hMBP peptides. Although virtually all hMBP peptides tested could be recognized by at least one TCL from MS patients, three immunodominant T cell epitopes were apparent among the TCL examined, corresponding exactly to the hMBP peptides capable of binding to several DR molecules. No major difference could be detected in the recognition of immunodominant hMBP peptides by TCL from DRB1*1501 positive or negative MS patients. These results have implications for the role of hMBP as relevant autoantigen, and of DRB1*1501 as susceptibility allele in MS. (J. Clin. Invest. 1993. 91:616-628.) Key words: immunodominance -human histocompatibilDr. Valli is currently at
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Introduction
Multiple sclerosis (MS)' is a chronic, inflammatory disease of the human central nervous system (CNS) characterized by demyelination and by focal infiltrates of macrophages, plasma cells, and T cells in the CNS (1) . Although the cause of MS is unknown, a T cell-dependent autoimmune process, involving autoreactive T cells specific for a myelin protein, has been postulated (reviewed in reference 2) and the demonstration of in vivo-activated T cells specific for human myelin basic protein (hMBP) in the blood of MS patients has implicated hMBP as a candidate autoantigen in the pathogenesis of MS (3) .
The possible role of hMBP in MS has been further supported by the observation that experimental allergic encephalomyelitis (EAE), an animal model for MS, can be induced by immunization with MBP or MBP peptides in adjuvant (4, 5) , as well as by passive transfer of MBP-specific CD4+ T cells (6) (7) (8) . Encephalitogenic T cells in mice and rats are specific for immunodominant MBP epitopes presented by specific MHC class II molecules; for example, in BIO.PL mice encephalitogenic T cells recognize the amino-terminal MBP peptide [1] [2] [3] [4] [5] [6] [7] [8] [9] presented by I-AU molecules (9) . The variable regions ofthe T cell receptor (TCR) in MBP-specific T cells have been found of limited heterogeneity, with a preferential expression of VB 8.2 and Va 2 or Va 4, both in mice and rats (10) . Thus, in these species, MHC class II and TCR gene products associated to recognition of encephalitogenic MBP epitopes by T cells have been identified. Recently, however, it has been demonstrated that EAE can be induced by other autoantigens, such as proteolipid protein ( 11) , raising the possibility that a multiplicity of myelin antigens may be capable oftriggering autoimmune reactions resulting in the clinical manifestations characteristic of EAE.
A significant association between major histocompatibility complex (MHC) class II gene products and disease has been observed in MS patients. The higher concordance rate for MS in monozygotic compared to dizygotic twins indicates a genetically determined susceptibility to the disease (12) . Because the frequency of the HLA class II allele DRB 1*1501, and of the associated DQB1 *0602, is significantly increased in Northern European MS patients compared to controls, DRB 1 * 1501, or gene(s) in linkage disequilibrium with it, could represent a susceptibility gene for MS ( 13, 14) . Although the DRBl * 1501 haplotype is associated with the highest relative risk of MS, other HLA class II alleles are overrepresented among certain ethnic groups of MS patients: DR4 in Southern Italians ( 15) and Arabs (16) and DR1 3 in Japanese (17) and Mexicans ( 18) . In contrast to the well-established association between HLA genes and MS, the association ofTCR genes, either in the germline ( 19, 20) or in the hMBP-specific peripheral T cell repertoire (21) (22) (23) (24) (25) , with MS is still unclear.
To assess the possible role of hMBP as autoantigen in MS, several groups have studied the epitope specificity of hMBPreactive T cells in MS patients and controls (26) (27) (28) (29) (30) (31) (32) . Autoreactive T cells, mostly CD4' and DR-restricted, specific for several hMBP peptides have been obtained from both MS patients and healthy controls. Although, collectively, major differences were not apparent in the T cell reactivity to hMBP between MS patients and controls, it has been suggested that recognition of immunodominant hMBP epitopes in individuals expressing an MS-associated HLA class II allele could be important in the pathogenesis ofthe disease. This would be expected ifhMBP is the autoantigen in MS, and if the role of the MS-associated class II alleles is to present hMBP peptides to autoreactive T cells.
To test this hypothesis, the binding of a panel of hMBP peptides to several purified DR molecules, including those associated to increased frequency of MS, was determined. In addition, T cell lines (TCL) specific for hMBP were established from MS patients positive or negative for the MS-associated allele HLA-DRB 1* 1501.
As demonstrated in the present study, some hMBP peptides bind with highest affinity to HLA class II molecules encoded by alleles associated to increased frequency of MS, thus providing a possible molecular explanation for the association between class II genes and MS, and at the same time implicating the hMBP sequence 84-103 as a possible candidate for the autoantigenic determinant. The finding that this peptide binds, with lower affinity, to several other DR molecules, may also provide an explanation for the incomplete association between MS and class II genes.
However, the observation that hMBP-specific T cells from either DRB1 * 1501 -positive or -negative MS patients recognize equally well this and other hMBP peptides cautions against a simplistic interpretation ofthe binding data, and illustrates the complexity and heterogeneity of T cell responses against hMBP.
Methods
Antigens. hMBP was prepared as described (33) . Purity ofhMBP preparations, as assessed by silver staining after gel electrophoresis, was routinely found to be > 90%. Peptides were synthetized on an Applied Biosystems Inc. (Foster City, CA) 430A peptide synthetizer. After removal of the a-amino-tert-butyloxycarbonyl protecting group, the phenylacetamidomethyl resin peptide was coupled with a fourfold excess of preformed symmetrical anhydride (hydroxybenzyltriazole esters for arginine, histidine, asparagine, and glutamine) for I h in dimethylformamide. For arginine, asparagine, glutamine, and histidine residues, the coupling step was repeated to obtain a high coupling efficiency. After synthesis was completed, the peptide was cleaved from the resin and the protecting groups removed by treatment with hydrogen fluoride in the presence of appropriate scavengers. The peptides were then purified by reversed phase high-performance liquid chromatography (HPLC). Peptide purity was substantiated by amino acid sequence and/or composition analysis. They were routinely > 95% pure after HPLC.
Affinity purification of DR molecules. The following EpsteinBarr virus (EBV)-transformed homozygous cell lines-LG2 (DRB1*0101), 3107 (DRB5*0101), MAT (DRBI*0301), PRIESS (DRBI*0404), BIN40 (DRBI*0404), SWEIG (DRBI*1101), PITOUT (DRBI*0701): or transfected fibroblasts-L466.1 (DRBI*1501), L416.3 (DRB5*0101), L242.5 (DRBI*1601), L255.1 (DRB5*0201)-were used as a source of HLA class II molecules. DRtransfected fibroblast were a kind gift of Dr. R. W. Karr (University of Iowa, Iowa City, IA). The HLA nomenclature is according to reference 34. Cell lines were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS) or horse serum (Hazelton Biologics, Inc., Lenexa, KS). Cells were lysed at a concentration of 108 cells/ml in 50 mM Tris-HCI, pH 8.5, containing 2% Renex, 150 mM NaCI, 5 mM EDTA, and 2 mM phenylmethyl sulfonyl fluoride (PMSF). The lysates were cleared of nuclei and debris by centrifugation at 10,000 g for 20 min.
DR molecules were purified essentially as described (35, 36) using the mab LB3.1 (37) 43) . Disease activity at the time of first blood sampling was also assessed by the same rater according to the following criteria: Active disease (1) was defined as ongoing deterioration or relapse of the disease during the preceding 2 wk. Clinically inactive (0) were considered all patients without any deterioration or relapse during the past 12 mo. Patients who did not meet these criteria were considered probably active (2) . In addition to the clinical assessment, magnetic resonance imaging (44, 45) 50 ,gM 2-mercaptoethanol, 50 ,g/ml gentamicin (Sigma Chemical Co., St. Louis, MO) and 10% heat-inactivated human AB positive serum. After 6 d of incubation at 37°C in a humidified atmosphere of 6% CO2 in air, 100 Ml of culture medium was replaced by fresh medium containing 20 U/ml human recombinant IL-2 (Hoffmann-La Roche, Basel). After 3-4 d the cultures were inspected microscopically for growth and positive cultures were split in complete medium with or without interleukin 2 (IL-2). After an additional 3-4 d, the latter cultures were washed twice and split into two adjacent microtiter wells. Irradiated (3,000 rad) autologous PBL ( 10' cells per well) were added to both wells and hMBP (30 Mg/ml) to one ofthem. hMBP-specific proliferation was measured by tritiated thymidine incorporation for the last 6 h of a 3-d culture period. At day 15, hMBP-specific cell lines grown in medium containing IL-2 were restimulated with autologous irradiated PBL (106/ml) and hMBP (30 Fig. 1 . All the 45 TCL tested were found to be restricted by a single HLA class II isotype. The majority of hMBP-specific TCL (38/45, 85%) were DR restricted. Few TCL (3/45, 6%) recognized hMBP peptides presented by DQ molecules. Interestingly, DQrestricted TCL were only obtained from MS patients homozygous for DQAl*0102/DQBI*0602. Some TCL (4/45, 9%) were restricted by DP molecules.
hMBP epitopes recognized by hMBP-specific TCLfrom MS patients. 61 hMBP-specific TCL established from 20 MS patients responded to one or more of the hMBP peptides tested. hMBP epitope(s) were recognized by -75% of the hMBPspecific TCL tested. Most T cell lines were specific for a single sequence of hMBP, but in some cases T cell proliferation to nonoverlapping hMBP peptides was observed. The proliferative response to hMBP and to synthetic hMBP peptides offour representative TCL is shown in Fig. 2 . The hMBP T cell epitopes recognized by all TCL tested, as well as the degree of responsiveness expressed as stimulation index, is presented in Table IV . T cell proliferation to hMBP and to hMBP peptides was dose dependent, and was usually induced by lower molar concentrations of the appropriate synthetic peptide, as compared to hMBP (Fig. 3) .
The 61 hMBP-specific TCL tested responded, overall, to 78 hMBP peptides. The hMBP peptides recognized by TCL, irrespective oftheir HLA restriction, are presented in Fig. 4 . Ofthe 16 hMBP peptides tested, 14 were recognized by at least one hMBP-specific TCL. Only two hMBP peptides, 23-42 and 74- (Table IV) . Results in Fig. 5 The DRB1 allele presenting hMBP peptides was determined by homozygous EBV-B cell-induced T cell proliferation for 12 TCL from DR-heterozygous patients (Table VI) Figure 1 . Characterization of HLA class II isotypic molecules presenting naturally processed hMBP peptides to hMBP-specific TCL. The HLA class II isotype restricting the anti-hMBP T cell response was assessed by inhibition of T cell proliferation by anti-DR, -DQ, and -DP monoclonal antibodies specific for HLA class II monomorphic determinants, as detailed in Methods. A description ofthese TCL is included in Table IV. class II isotype restriction by antibody blocking was available, are also included. These results demonstrate that the dominant epitopes 84-103 and 144-163 can be presented by different class II molecules, as expected from their degenerate binding capacity (Tables I and II) . In particular, the peptide 84-103 can be presented to TCL by DRBl * 1302, DRB1 * 1101, and DRB 1 * 1501 (or DRB5*0101) molecules. The peptide 144-163 can be presented by at least four DR molecules: DRB1*0101, DRBl*l 101, DRBl*1301, and DRB1*1501 (or DRB5*01 01), further demonstrating the functional relevance of binding data.
These results highlight three points relevant to recognition of hMBP epitopes by TCL from DRB1 * 1501 -positive MS patients. First, APC from MS patients carrying the DRB 1 * 1501 haplotype can present to TCL at least six different hMBP peptides. Second, these peptides are not all presented by DRBI*1501 (or DRB5*0101 ) molecules. Third, in some cases the same peptide, e.g., 104-123, can be presented by either DR or DQ molecules.
Discussion
Based on experimental models of MS, hMBP is considered a likely candidate for the selfantigen recognized by autoreactive, pathogenic human T cells capable of mediating MS (2, 55) .
In the present study we have systematically analyzed the binding of overlapping peptides encompassing the entire hMBP molecule to several HLA class II molecules, and correlated their binding capacity to the recognition of hMBP peptides by HLA class II-restricted TCL. In particular, we have focused on thebinding ofhMBP peptides to HLA class II molecules associated or not to increased susceptibility to MS, and on the analysis of hMBP-specific TCL from MS patients expressing or not these susceptibility alleles. Although the emerging pattern is complex, some points appear to be quite clear.
Several hMBP peptides bind with high affinity to one or two of the HLA class II molecules tested. In addition, three hMBP determinants, included in sequences 13-32, 84-103, and 144-163 exhibit degenerate binding, since they are able to form complexes with several of the HLA class II molecules examined. Degenerate binding ofpeptides to HLA class II molecules is not unprecedented because it has been described for peptides derived from malaria circumsporozoite protein (56), tetanus toxoid (57), and influenza hemagglutinin (41, 58, 59 Immunodominance of T cell epitopes is certainly influenced by many mechanisms (60) peptide expressing the most degenerate binding pattern, since it binds to 8 out ofthe 10 DR molecules tested. In particular, this peptide binds with highest affinity, in the low nM range, to class II molecules encoded by DRB1* 1501 and DRB 1*0401 alleles. Because these alleles are associated to increased frequency of MS in Northern ( 14) and Southern ( 15) European populations, respectively, the results would suggest that high affinity binding of this hMBP peptide may be relevant to the pathogenesis ofMS. Conversely, the other major immunodominant peptide, 144-163, binds very weakly to DRB1 *1501 and DRB1*0401 molecules. A point of debate is the binding affinity of autoantigenic peptides for the class II molecules associated to disease susceptibility. According to one theory, autoreactive pathogenic T cell clones could recognize low affinity binders, and for this reason have escaped thymic deletion during negative selection (61 ) . The opposite view considers autoantigenic peptides as high affinity binders, and therefore highly antigenic. When events such as molecular mimicry (62) or regulatory imbalances (63) lead to breakdown oftolerance, their antigenic potential can be expressed. The hMBP peptide centered on the sequence 84-103 is a high-affinity binder to the DR molecules associated with increased frequency of MS. In analogy with binding of MBP peptides to mouse class II molecules (64) , this result would suggest that high affinity binding may be necessary for a self peptide to become a dominant determinant recognized by autoreactive T cells.
Considering the binding data, and especially degeneracy of binding, it is therefore perhaps not surprising to find that the hMBP peptides 84-103 and 144-163 represent dominant epitopes recognized by about 30% of hMBP-specific TCL. In that only 84-103 binds with high affinity to DR molecules associated with increased frequency ofMS, it would be tempting to infer that this epitope may be relevant to disease induction and/or progression. However, both immunodominant hMBP epitopes are recognized with the same frequency by TCL from DRB1*1501-positive or -negative MS patients. Moreover, in the three MS patients homozygous for DRB 1*1501 many hMBP peptides are recognized by TCL in addition to 84-103, and in at least three of these TCL the response is restricted by since polymorphism in Lmp genes may result in the production ofdifferent peptides in different individuals, and polymorphism in Tap genes may influence peptide loading of HLA molecules (65) . Third, our evaluation of hMBP epitopes recognized by TCL from MS patients was conducted, as in any study of this type, on PBL and therefore the T cells infiltrating the inflammation site in the CNS were not directly assessed.
Fourth, MS was already clinically evident in all the patients tested at least 1 yr before establishment ofhMBP-specific TCL, and it is expected that in the course of autoimmune diseases T cells not involved in disease induction may also become recruited (66) . This obviously also applies to nonpathogenic T cells specific for hMBP epitopes.
In conclusion, the fact that hMBP 84-103 binds preferentially to the HLA class II molecules encoded by alleles associated to increased MS frequency could be consistent with its proposed role in the pathogenesis of MS (29, 67) . Because the other major dominant peptide, 144-163, binds very weakly to DR molecules encoded by MS susceptibility alleles, we favor the hypothesis that this epitope is not involved in the pathogenesis of MS (29) . The finding that peptide 84-103 also binds to several DR molecules not associated with disease may explain why many MS patients do not carry the DRB1 *1501 susceptibility allele. In fact, recognition of hMBP peptides by TCL from MS patients does not appear to be directly linked to the putative HLA susceptibility alleles, because very similar hMBP immunodominant epitopes are recognized by TCL from DRB 1 * 150 1-positive or -negative MS patients. It would be interesting to know whether selective immunotherapies ofestablished MS based on hMBP as autoantigen (2) may influence the course ofdisease, although, considering all this complexity, the approach may prove more problematic than originally anticipated.
